Montelukast Aristo

Montelukast, the active ingredient in Montelukast Aristo, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional and is used under prescription in the European Union market.

GNH USA supplies Montelukast Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Montelukast is a leukotriene receptor antagonist used to treat conditions involving airway inflammation and allergic symptoms.

Asthma: helps decrease airway inflammation and bronchoconstriction, leading to fewer symptoms such as wheezing, coughing and shortness of breath, and reduces the need for rescue inhaler use. Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea by blocking leukotriene‑mediated inflammation in the nasal passages, and improves overall nasal airflow. Exercise‑induced bronchoconstriction: prevents the narrowing of airways that can occur during or after physical exertion, improving exercise tolerance, and supports consistent participation in sports or physical activities.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate head pain that may be intermittent. - Abdominal pain: discomfort or cramping in the stomach region. - Cough: occasional dry cough without mucus production. - Nausea: feeling of queasiness that may precede vomiting. - Dizziness: light‑headed sensation, especially when standing quickly. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling of face or throat, potentially leading to anaphylaxis. - Mood changes: new or worsening depression, anxiety, or thoughts of self‑harm. - Liver enzyme elevation: increased ALT/AST indicating possible hepatic injury. - Eosinophilic granulomatosis with polyangiitis: rare systemic vasculitis presenting with asthma worsening and eosinophilia.

Precautions should be observed when prescribing Montelukast. - Pregnancy: consult a healthcare provider; safety not established. - Breastfeeding: weigh potential benefits against possible risks. - Pediatric use: dosage determined by age/weight; monitor for behavioral changes. - Elderly: start at lowest effective dose and monitor for adverse effects. - Drug interactions: review concomitant medications for potential interactions. - Renal impairment: use with caution; monitor renal function. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and light.

Montelukast can interact with other medicines, affecting its concentration or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can raise montelukast levels, increasing risk of adverse effects. - Phenobarbital: enzyme induction may lower montelukast exposure, reducing efficacy. - Carbamazepine: potent inducer of hepatic enzymes that can markedly decrease montelukast concentrations.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may modestly increase montelukast levels; monitor for side effects. - Warfarin: possible alteration of anticoagulant effect; check INR regularly when co‑administered.